Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous CD19 CAR-expressing CD4+/CD8+ T cells MB-CART19.1

A preparation of CD4+ and CD8+ autologous T lymphocytes transduced with the lentiviral vector pLTG1563 expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR-expressing CD4+/CD8+ T cells MB-CART19.1 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CD19 CAR-transduced CD4/CD8 enriched T cells MB-CART19.1
Code name:MB CART19.1
MB-CART19.1
MBCART19.1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search